Company Profile
Public information reviewed
AN2 Therapeutics, Inc.
Canonical company identity and public leadership record.
USNASDAQ: ANTX
Follow
More
- Public sources
- 1 reviewed
- Published leadership records
- 16
- Last reviewed
- Sep 16, 2026
Agent View
Machine representations
Inspect the same governed public record as Markdown, structured data, or a retrieval endpoint.
Markdown
https://registry.alpha.ac/companies/an2-therapeutics-inc.mdAN2 Therapeutics, Inc.
Alpha governed public record. Unknown, unavailable, and unpublished values are never inferred as zero.
Record
| Field | Value |
|---|---|
| Representation | alpha-profile-markdown-v3 |
| Protocol | Alpha Governance Facts Protocol 0.1 |
| Schema | alpha.governance.entity.public.v1 |
| Record version | public-1 |
| Canonical entity | alpha:company:b92e141d-3c35-4f76-afa0-2d12534e9412 |
| Entity type | Company |
| Canonical URL | https://registry.alpha.ac/companies/an2-therapeutics-inc |
| Publication | PUBLISHED |
| Verification | source_reported |
| Verification schema | alpha-verification-states-v1 |
| Ownership | unclaimed |
| Published claims | 19 |
| Claims under review | 1 |
| Evidence records | 3 |
| Conflicts | 0 |
| Conflicts in internal review | 0 |
| Observed | 2026-09-16T04:46:30.336153+00:00 |
| Last reviewed | 2026-09-16T04:46:30.336153+00:00 |
Identity
- Legal name: AN2 Therapeutics, Inc.
- Display name: AN2 Therapeutics, Inc.
Leadership
- Eric Easom: President, Chief Executive Officer and Board Chair. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:b92e141d-3c35-4f76-afa0-2d12534e9412:2.
- Gilbert Lynn Marks: Director. Valid from: 2020-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:b92e141d-3c35-4f76-afa0-2d12534e9412:3.
- Gilbert Lynn Marks, M.D.: Class I Director. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:b92e141d-3c35-4f76-afa0-2d12534e9412:2.
- Joseph Zakrzewski: Class III Director. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:b92e141d-3c35-4f76-afa0-2d12534e9412:2.
- Kabeer Aziz: Class I Director. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:b92e141d-3c35-4f76-afa0-2d12534e9412:2.
- Margaret FitzPatrick: Class II Director. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:b92e141d-3c35-4f76-afa0-2d12534e9412:2.
- Melvin Spigelman: Director. Valid from: 2022-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:b92e141d-3c35-4f76-afa0-2d12534e9412:3.
- Melvin Spigelman, M.D.: Class II Director. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:b92e141d-3c35-4f76-afa0-2d12534e9412:2.
- Patricia Martin: Class II Director. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:b92e141d-3c35-4f76-afa0-2d12534e9412:2.
- Rob Readnour: Director. Valid from: 2019-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:b92e141d-3c35-4f76-afa0-2d12534e9412:3.
- Rob Readnour, Ph.D.: Class I Director. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:b92e141d-3c35-4f76-afa0-2d12534e9412:2.
- Stephanie Wong: Class III Director. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:b92e141d-3c35-4f76-afa0-2d12534e9412:2.
- Eric Easom: President, Chief Executive Officer and Board Chair. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:b92e141d-3c35-4f76-afa0-2d12534e9412:2.
- Joshua Eizen: Chief Legal Officer and Chief Operating Officer. Valid from: 2026-04-22. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:b92e141d-3c35-4f76-afa0-2d12534e9412:3.
- Lucy Day: Chief Financial Officer. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:b92e141d-3c35-4f76-afa0-2d12534e9412:2.
- Sanjay Chanda, Ph.D.: Chief Development Officer. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:b92e141d-3c35-4f76-afa0-2d12534e9412:2.
Roles
- PUBLISHED
Governance
- NOT_ASSERTED
Board committees
- PUBLISHED
Financials
- NOT_ASSERTED
Workforce
- NOT_ASSERTED
Market and index context
- PUBLISHED
Legal Name
- AN2 Therapeutics, Inc.. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:b92e141d-3c35-4f76-afa0-2d12534e9412:1.
Headquarters
- US. Publication: UNDER_REVIEW. Verification: source_reported. Assertion: source_reported. Evidence: unlinked, under review.
Entity Status
- Public listing published. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:b92e141d-3c35-4f76-afa0-2d12534e9412:1.
Published Fact
- US. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:b92e141d-3c35-4f76-afa0-2d12534e9412:1.
Coverage states
| Field | Value |
|---|---|
| Identity | PUBLISHED |
| Business | PUBLISHED |
| Leadership | PUBLISHED |
| Board and committees | PUBLISHED |
| Governance | NOT_ASSERTED |
| Financials | NOT_ASSERTED |
| Workforce | NOT_ASSERTED |
| Ownership | NOT_ASSERTED |
| Ratings | NOT_PUBLISHED |
| Market and index context | PUBLISHED |
Public sources
- alpha:evidence:company:b92e141d-3c35-4f76-afa0-2d12534e9412:1: Alpha canonical company public projection.
- alpha:evidence:company:b92e141d-3c35-4f76-afa0-2d12534e9412:2: SEC DEF 14A 0001193125-26-170314.
- alpha:evidence:company:b92e141d-3c35-4f76-afa0-2d12534e9412:3: DEF 14A antx-20260422.htm.
Rights
| Field | Value |
|---|---|
| public_retrieval | allowed |
| agent_retrieval | allowed |
| redistribution | not_granted |
| model_training | not_granted |
| commercial_use | not_specified |
| relationship_pathfinding | not_granted |
| direct_contact | not_granted |
Limitations
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.
Alternate representations
- Canonical profile
- Public Markdown
- Public JSON
- JSON-LD
- MCP resource:
alpha://companies/an2-therapeutics-incat https://mcp.alpha.ac/mcp